ZA888817B - Sustained(controlled)release delivery system for substituted dihydropyridine calcium channel blockers - Google Patents

Sustained(controlled)release delivery system for substituted dihydropyridine calcium channel blockers

Info

Publication number
ZA888817B
ZA888817B ZA888817A ZA888817A ZA888817B ZA 888817 B ZA888817 B ZA 888817B ZA 888817 A ZA888817 A ZA 888817A ZA 888817 A ZA888817 A ZA 888817A ZA 888817 B ZA888817 B ZA 888817B
Authority
ZA
South Africa
Prior art keywords
sustained
controlled
delivery system
calcium channel
channel blockers
Prior art date
Application number
ZA888817A
Other languages
English (en)
Inventor
Madurai Gurusamy Ganesan
Gurusamy Ganesan Madurai
Narendra Ragjunathji Desai
Ragjunathji Desai Narendra
Gary Arthur Maier
Arthur Maier Gary
Prakash Shriram Kulkarni
Shriram Kulkarni Prakash
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ZA888817B publication Critical patent/ZA888817B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
ZA888817A 1987-11-25 1988-11-24 Sustained(controlled)release delivery system for substituted dihydropyridine calcium channel blockers ZA888817B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12544087A 1987-11-25 1987-11-25

Publications (1)

Publication Number Publication Date
ZA888817B true ZA888817B (en) 1989-08-30

Family

ID=22419737

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA888817A ZA888817B (en) 1987-11-25 1988-11-24 Sustained(controlled)release delivery system for substituted dihydropyridine calcium channel blockers

Country Status (15)

Country Link
EP (1) EP0317780B1 (enExample)
JP (1) JPH02655A (enExample)
KR (1) KR890007746A (enExample)
AT (1) ATE76292T1 (enExample)
AU (1) AU626187B2 (enExample)
DE (1) DE3871343D1 (enExample)
DK (1) DK656488A (enExample)
ES (1) ES2037179T3 (enExample)
FI (1) FI885454L (enExample)
GR (1) GR3004988T3 (enExample)
IL (1) IL88197A0 (enExample)
NO (1) NO885246L (enExample)
NZ (1) NZ226987A (enExample)
PT (1) PT89055A (enExample)
ZA (1) ZA888817B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4117784A1 (de) * 1991-05-31 1992-12-03 Basf Ag Herstellung von protein-polyalkylenglykolkonjugaten
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
EP0632082B1 (en) * 1993-06-29 1997-04-02 "HEYLECINA", Société Anonyme Preparation of activated carbamates of poly(alkylene glycol) and their use
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
CA2277220A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
SE9704401D0 (sv) * 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7071426B2 (en) 2002-12-09 2006-07-04 Ishida Co., Ltd. Combination weighing device with multi-layered hoppers having controllable supply function
WO2004110354A2 (en) 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
US7754897B2 (en) 2005-06-15 2010-07-13 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
US7705036B2 (en) 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
WO2005094897A2 (en) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
EP1828099B1 (en) 2004-11-18 2020-01-22 Correvio International Sàrl Synthetic process for aminocyclohexyl ether compounds
ES2449594T3 (es) 2007-10-05 2014-03-20 Alzheimer's Institute Of America, Inc. Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA959759A (en) * 1970-01-15 1974-12-24 John J. Miskel Method for absorption of drugs
FR2518403B1 (fr) * 1981-12-22 1987-01-02 Dietlin Francois Procede de preparation de formes pharmaceutiques presentant une resorption par voie digestive amelioree, et les formes pharmaceutiques ainsi obtenues
IT1174779B (it) * 1982-09-27 1987-07-01 Sandoz Ag L'impiego in terapeutica dei derivati della 1,4-di idropiridina
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device

Also Published As

Publication number Publication date
EP0317780A1 (en) 1989-05-31
FI885454A0 (fi) 1988-11-24
NO885246L (no) 1989-05-26
NZ226987A (en) 1992-04-28
JPH02655A (ja) 1990-01-05
KR890007746A (ko) 1989-07-05
EP0317780B1 (en) 1992-05-20
FI885454A7 (fi) 1989-05-26
NO885246D0 (no) 1988-11-24
ATE76292T1 (de) 1992-06-15
DK656488D0 (da) 1988-11-24
ES2037179T3 (es) 1993-06-16
AU626187B2 (en) 1992-07-23
AU2587088A (en) 1989-05-25
IL88197A0 (en) 1989-06-30
DE3871343D1 (de) 1992-06-25
PT89055A (pt) 1989-11-30
FI885454L (fi) 1989-05-26
GR3004988T3 (enExample) 1993-04-28
DK656488A (da) 1989-05-26

Similar Documents

Publication Publication Date Title
ZA888817B (en) Sustained(controlled)release delivery system for substituted dihydropyridine calcium channel blockers
KR960009411B1 (en) Controlled release preparation containing metoprolol and dihydropyridine
YU57689A (en) Compositions of transite metals, bridged by silicon
IL85078A0 (en) 3'-azido-2',3'-dideoxyuridine anti-retroviral composition
AU7895387A (en) Living polymers from unsaturated si, sn or ge initiators
ATE100461T1 (de) 2',3'-dideoxy-2'-fluornucleoside.
FI901328A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisen (7 ,17 )-17-hydroksi-7-metyyli-19-nor-17-pregn-5(10)-en-20-yn-3-onin valmistamiseksi kiteisenä puhtaana muotona
EP0244189A3 (en) Human pancreatic elastase i
GR870824B (en) Process for the preparation of new 1,4 - dihydropyridines useful as antithrombotic drugs
EP0243571A3 (en) Initiator system for polymerization of 1,3-dienes or copolymers containing 1,3-dienes
TW245740B (enExample)
ES2038665T3 (es) Procedimiento de sintesis de penems.
SE8700361D0 (sv) Immunosuppressant agents
AU8191587A (en) 1,2,3,9-tetrahydro-9-methyl-3(2-methyl-1h-imidazol-1-yl) methyl)4h-carbazol-4-one for gastrointestinal disorder treatment
ATE90098T1 (de) Cycloalkan(1,2-c:4,3-c'>dipyrazole.
AU6478490A (en) Process for the molecular weight regulation of poly(dichlorophosphazenes)
ES2061602T3 (es) Polimeros acrilicos imidizados y procedimiento para su preparacion.
GR3022713T3 (en) Process for the vacylation of threonine derivatives and their use in the preparation of 1,4-dihydropyridines.
IT217687Z2 (it) Struttura di calzatura, particolarmente per l'arrampicata libera.
PT89493A (pt) Processo de preparacao do 3-(piridil-3)-1h,3h-pirrol {1,2-c} tiazolcarbonitrilo-7
GB8910205D0 (en) 2,6-dimethyl-1,4-dihydrophyridine-3,5-dicarboxylic acid adamentyl esters
NO884264L (no) 3'-azido-2',3'-dideoksyuridin-anti-retrovirus-blanding.
IE880214L (en) 3'-azido-2',3'-dideoxyuridine anti-retroviral compositions
IT8719368A0 (it) Composizione solida, resistente all'idrolisi, stabilizzante per i polimeri organici e procedimento per la sua preparazione.
AU2231388A (en) Ocular hypotensive agents